Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Jul 2019: Trial started, NCT04035486
  2. 29 Jul 2019: Trial registered, NCT04035486

The trials

NCT04035486: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

State
Under way
Phase
Phase 3
People
587 taking part
Started
2 Jul 2019
Primary completion
3 Apr 2023
Arms
Osimertinib 80 mg QD and platinum-based chemotherapy
Results
Posted on the registry
  1. 2 Jul 2019: Trial started
  2. 29 Jul 2019: Trial registered
  3. 6 Aug 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.